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httpcense.Abstract With the judicious use of inhaled corticosteroids (ICS) and B2 agonists most patients
with asthma are easily controlled and managed. However, approximately 5–10% of asthmatics
did not respond to standard therapy and are classiﬁed as ‘‘difﬁcult to treat asthma, DTA’’. Many
factors can contribute to poor response to conventional therapy. For these patients, a systematic
approach is needed to identify false (non-genuine) DTA from true (genuine) intractable DTA. It
is essential to sort through and address the above issues before reverting to other therapy.
Objectives: The aim of the present study is to evaluate a systematic approach to indentify the
patients of false (non-genuine) to true (genuine) DTA and to recognize the underlying different pre-
cipitating factors.
Conclusion: In apparently DTA there is a high prevalence of false (non-genuine) cases. Identiﬁ-
cation and management can be achieved by detailed systematic assessment.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Asthma is a major public health problem. Its worldwide
prevalence is estimated at 10% and is still increasing [1–4].
Small percentage of asthmatic patients (5–10%) are
not well controlled despite the use of high dose inhaled6501943.
om (M. Amin).
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://dx.doi.org/10.1016/j.ejcdt.2013.1corticosteroids (ICS), long actingbronchodilators (LABA), plus
addon treatment.These patients are attributed tohaveDifﬁcult-
to-treat asthma (DTA) [5]. DTA carries several names; each one
points to an aspect of the disease. ‘‘Chronic severe asthma’’ [5],
‘‘steroid-dependent asthma’’ [6], ‘‘steroid-resistant asthma’’ [7],
‘‘difﬁcult-to-control asthma’’ [5], ‘‘resistant asthma’’ [6] and
‘‘refractory asthma’’ [7] are some of these terminologies.
Although these patientsmake small percentage of all asthmatics,
they account for 50% of the total cost of asthma therapy [8].
Mortality, morbidity, steroid side effects and health costs are
disproportionately high in these patients, and they are at greater
risk of acute severe, near fatal, and fatal exacerbations [7].
Many factors can contribute to poor response to conventional
therapy. For these patients, a systematic approach is needed to
identify false (non-genuine) from true genuine intractableDTA [9].he Egyptian Society of Chest Diseases and Tuberculosis.
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40 M. Amin et al.False (non-genuine causes) DTA can be divided into three
categories: (1) misdiagnosis where the problem is not asthma
from start [10] (e.g. psychiatric disorders, chronic obstructive
pulmonary disease (COPD), congestive heart failure (CHF),
interstitial lung disease (ILD), upper airway disease (UAWD),
bronchiolitis obliterans (BO), and pulmonary inﬁltrates with
esinophilia (PIE)), (2) presence of confounding factors (e.g.
poor inhaler technique, persistent exposure to provoking fac-
tors, non-adherence to treatment and drug intake e.g. NSAIDs
or B blockers) and (3) comorbidities that worsen asthma and
making it difﬁcult to treat (e.g. chronic rhinosinus disease, gas-
troesophageal reﬂux disease (GERD), obstructive sleep apnea
syndrome (OSA), psychiatric disorders, vocal cord dysfunction
syndrome (VCD) and hypothyroidism) [11]. It is essential to
sort through and address the above issues before reverting to
other therapy [12–14].
Aim of the present study
The aim of the present study is to evaluate a systematic ap-
proach to identify false (non-genuine) to true (genuine) DTA
patients and to recognize the prevalence of the underlying dif-
ferent precipitating factors.
Patients and methods
The present cross-sectional study was performed in the outpa-
tient asthma clinic, Fayoum University Hospital, Department
of Chest Diseases, Faculty of Medicine, Fayoum University.
In this study, 200 patients provisionally diagnosed as appar-
ently DTA aged 9–69 yrs, were consecutively recruited from
7 different general hospitals, many primary health care units,
many private clinics in the region of Fayoum Governorate.
The patients were all treated with P2000 lg day1 of
beclomethazone dipropionate (BDP) or its equivalents with
long-acting bronchodilators. DTA was deﬁned on the basis
of clinical assessment, treatment requirements and fulﬁll the
diagnostic criteria of DTA according to the American
Thoracic Society [7,15]. Patients were all nonsmokers or light
smokers (smoking history < 10 pack-yrs) [14].
At the ﬁrst visit, patients’ characteristics were documented
according to a structured questionnaire. Full clinical history
was recorded for all subjects and a thorough physical examina-
tion was performed. All patients were submitted for routine
laboratory proﬁle, CXR, pulse oximetry for arterial oxygen
saturation and forced spirometry with reversibility testing.
Diagnosis of asthma was deﬁned on the basis of typical symp-
toms together with current or recently documented reversibil-
ity in forced expiratory volume in 1st second (FEV1) of
>15%. FEV1 was assessed before and 30 min after the
nebulization by 5 mg salbutaomol and 500 lg ipratropium
and expressed as percentage of predicted value [16]. Reversibil-
ity in FEV1 was deﬁned as follows [16]: FEV1 POSTð
FEV1 PRE=FEV1 PREÞ. In non-asthmatic patients, we search
for another disease causing these misdiagnoses. General
Health Questionnaire (GHQ) was used to evaluate each pa-
tient’s psychological functioning. This is the most widely used
scoring test used to detect psychiatric disorders in medical
practice. It measures the presence of non-psychotic psychiatric
disturbances speciﬁcally anxiety and depression disorders. The
short GHQ-12 version (score range 0–12) was used, with ascore P6 indicating possible psychiatric cases [17]. COPD
was diagnosed according to GINA criteria [1]. CHF was
diagnosed according to clinical, radiological and echocardio-
graphic criteria. ILD was diagnosed according to clinical,
functional and HRCT chest criteria. Bronchiectasis was diag-
nosed according to clinical and HRCT chest criteria. UAWD
was diagnosed according to clinical, ﬂow-volume loop, radio-
logical, and ﬁberoptic laryngoscopic criteria. BO was diag-
nosed according to clinical, functional, and HRCT chest
criteria. PIE was diagnosed according to clinical, laboratory,
radiological and bronchoalveolar lavage ﬁndings [6,7].
At the second visit, confounding factors were reviewed
(either poor inhaler technique, persistent exposure to provok-
ing factors, poor adherence or drug intake e.g. NSAIDs, B
blockers). Inhaler technique was reviewed and patients were
provided with the device they found most suitable and could
use properly (including the provision of combination inhalers).
Detailed history was taken to detect any persistent indoor or
outdoor exposure to provoking factors (either non-speciﬁc or
speciﬁc allergens). If an external provoking factor was identi-
ﬁed for example, occupational exposure, domestic allergen or
particular food-subjects were encouraged to take steps to ex-
clude the provoking factor.
At the third visit precipitating comorbidities that worsen
asthma and making it difﬁcult to treat were reviewed. Severe
rhinosinus disease was considered to be present if there are
symptoms of itching of nose, sneeze, rhinorrhoea, nasal
obstruction or post-nasal discharge with a successful trail of
topical steroids, oral antihistaminics and alkaline nasal wash.
If there is no improvement the patient was shifted to ENT
clinic. GERD was considered to be present if there is severe re-
ﬂux symptoms improved with a successful trial of proton-
pump inhibitors and GIT prokinetics. OSA was considered a
potential contributing factor if the clinical criteria were met
by overnight pulse oximetry revealed AHI >5/h [10]. General
Health Questionnaire (GHQ) was used to evaluate each pa-
tient’s psychological functioning as previously mentioned.
Vocal cord dysfunction syndrome was considered to be present
if there are clinical symptoms of noisy breathing and dyspnea,
laryngoscopic evidence of vocal cord adduction with or with-
out ﬂattening of the inspiratory limb of ﬂow-volume loop
[18]. Hyperthyroidism was present with an elevated level of
free thyroxin (>24 pmol L1) [17].
All patients were followed up for a minimum period of
3 months after protocol assessment. If asthma symptoms were
controlled, subjects are classiﬁed as having false (non-genuine)
DTA and were discharged. Co-existent diagnoses were man-
aged using standard treatments.Results
Prevalence of potential contributing factors in the 200 patients
with DTA who participated in the study and patients’ charac-
teristics are given in Tables 1–4 and Figs. 1, 2.Discussion
The results of the present study show that 90% of the appar-
ently diagnosed DTA may not so be. False (non-genuine)
DTA in these patients were strongly associated with
Table 2 Percentage of false (non-genuine) to true (genuine)
DTA patients.
Subjects n 200
False (non-genuine) DTA 180 (90%)
True (genuine) DTA 20 (10%)
Table 3 Potential prognostic factors at presentation for
having true (genuine) DTA after variables were dichotomized
using logistic regression analysis.
ICS > 2000 lg at referral 7.4 (3.5–21.7)
Previous pulmonologist attendance 3.9 (2.7–13.6)
Pre-bronchodilator FEV1 < 70% 5.1 (3.2–14.7)
Table 4 Prevalence of underlying different factors in false
(non-genuine) DTA.
Subjects n 180
Misdiagnosis 60/180 (33%)
Psychiatric disorders 18/60 (30%)
COPD 15/60 (25%)
CHF 9/60 (15%)
ILD 7/60 (11.6%)
Bronchiectasis 5/60 (8.3%)
UAWD 3/60 (5%)
BO 2/60 (3.3%)
PIE 1/60 (1.6%)
Confounding factors 40/180 (22.2%)
Poor inhaler technique 20/40 (50%)
Persistent exposure 20 (50%)
Poor adherence 13/40 (32.5%)
Drug intake 9/40 (15%)
Comorbidities 80/180 (44.4%)
Severe rhinosinus disease 65/80 (81%)
GERD 56/80 (70%)
OSA 25/80 (31%)
Psychiatric disorders 23/80 (28%)
VCD 15/80 (18%)
Hyperthyroidism 6/80 (7%)
COPD= chronic obstructive pulmonary disease, CHF= conges-
tive heart disease, ILD= interstitial lung disease, UAWD= upper
airway disease, BO = bronchiolitis obliterans, PIE = pulmonary
inﬁltrates with esinophilia, VCD= vocal cord dysfunction,
GERD= gastroesophageal reﬂux disease, OSA= obstructive
sleep apnea.
Figure 1 Percentage of underlying comorbidities in the 80
patients who conﬁrmed to be asthmatic and have another
comorbidities which lead to their poor control (n= 80).
SSS = severe rhinosinus disease, GERD= gastroesophageal
reﬂux disease, OSA = obstructive sleep apnea syndrome, Ps
dis = psychiatric disease, VCD= vocal cord dysfunction syn-
drome, Hypthy = hyperthyroidism.
Figure 2 Frequency distribution of comorbid factors (severe
rhinosinus disease, GERD, OSA, psychiatric disorder, VCD,
hyperthyroidism) which leads to poor control asthma. 1: one
comorbid factor (occur in 16% of these group of patients); 2: two
comorbid factors (35%); 3: three comorbid factors (44%); 4: four
comorbid factors (5%).
Table 1 Patient characteristics of the study population.
Subjects n 200
Age yrs 41.6 ± 32.6
Female % 70%
Age at onset asthma yrs 8.9 (0.7–60)
Asthma duration yrs 18.0 (3–61)
Dose of ICSa 1500 (1500–4000)
Maintenance oral steroids % 10
Smoking history pack.yrs1 3 (0–10)
a Beclomethasone dipropionate or its equivalent in lg/day.
Difﬁcult to treatment asthma, is it really asthma? 41misdiagnosis (33% of false DTA). These misdiagnosed dis-
eases may be psychiatric disorders (30%), COPD (25%),
CHF (15%), ILD (11.6%), bronchiectasis (8.3%), UAWD
(5%), BO (3.3%) or PIE (1.6%). 22.2% of false (non-genuine)
DTA are due to confounding factors (e.g. poor inhaler tech-
nique (50%), persistent exposure to speciﬁc or non-speciﬁc
provoking factors (50%), poor adherence (32.5%) or drug in-
take (15%)). 44.4% of false (non-genuine) DTA are due to
underlying unrecognized comorbidities. Severe rhinosinus
disease occurs in 81% of patients in this group, while GERD
occurs in 70%, OSA in 31%, psychiatric disorders in 28%,
VCD in 18% and hyperthyroidism in 7%.
These ﬁndings emphasize the high prevalence of misdiag-
nosed asthma, presence of mostly unidentiﬁed confounding
factors or existence of underlying unrecognized comorbidities.
The ﬁndings of the present study suggest that the management
of these factors may result in better control of the disease. A
systematic evaluation protocol facilitates recognition and man-
agement of these factors and allows identiﬁcation of the small
sector – but troublesome – of these patients with true (genuine)
DTA. Clinical improvement can be anticipated if patients with
poorly controlled or DTA are submitted to a systematic eval-
uation protocol [19–20].
One previous systematic evaluation protocol for patients
with DTA has been published [20]. This protocol evaluated
42 patients over an 8 yr period from 1982 to 1990 and con-
cluded that, after working through the protocol, 74% were
42 M. Amin et al.no longer difﬁcult to control which suggests that protocol
guided care improves outcome both in terms of lung function
and patients symptoms.
The present study reveals that patients with true (genuine)
DTA tend to have both lower initial FEV1% and lower best
FEV1% which are consistent with a greater degree of ﬁxed air-
ﬂow obstruction and airways remodeling. These ﬁxed airﬂow
obstruction and airway remodeling does not relate to the pres-
ence of previous or current smoking. This is consistent with
previous studies showing signiﬁcantly reduced lung function
in subjects with severe asthma [21,22].
As our study was cross sectional, it is impossible to deter-
mine whether worse lung function causes true (genuine)
DTA or vice versa. Given the prolonged period of instability
and the fact that there was no difference in the duration of
asthma, these observations suggest that unstable disease
(which could be due to uncontrolled or a particular type of
therapy resistant inﬂammation) is associated with progressive
remodeling and an accelerated decline in lung function.
As anticipated, identifying a diagnosis in addition to asthma
which contributed to symptoms was associated with false (non-
genuine)DTA. In addition, prior assessment by another respiratory
specialist was associatedwith true (genuine)DTA, although this did
not appear tobe related to the identiﬁcationof additional diagnoses.
The present study suspect three variables (inhaled steroid
dose P2000 lg, pre-bronchodilator FEV1 of <70% on this
dose of inhaled steroid, and previous respiratory specialist refer-
ral) which reﬂect relative steroid resistance and chronic unstable
disease. It is interesting that a prebronchodilator FEV1 of
<70% at presentation despite high dose inhaled steroids and
long acting b2 agonist predicted resistance to treatment.
In the true (genuine) DTA group the prebronchodilator
FEV1% at presentation was signiﬁcantly lower than the best
pre-bronchodilator FEV1% during follow up, suggesting that
it is the inability to maintain lung function at a certain level de-
spite intensive treatment rather than the degree of ﬁxed airﬂow
obstruction that deﬁnes therapy resistant disease.Conclusions
The present study evaluates a cohort of sequentially referred
patients with apparently DTA. 90% of them have false
(non-genuine) DTA due to misdiagnoses, presence of con-
founding factors or existence of underlying unrecognized
comorbidities. These data support the use of a detailed and
systematic evaluation of this population.Conﬂict of interest
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